Chapter 10 Study Guide: Lysergic Acid Diethylamide (LSD)

LSD Source & Structure:

• LSD is a semisynthetic ergoline derivative synthesized by combining lysergic acid (derived from the ergot fungus, Claviceps purpurea) with diethylamine. 

Extreme Potency:

LSD is biologically active at microgram quantities. Typical active clinical/recreational doses range from 100 to 250 μg (0.10 to 0.25 mg). In comparison, psilocybin is administered at 10–25 mg (two orders of magnitude larger), and mescaline is dosed at 200–500 mg (three orders of magnitude larger).

Absorption & Bioavailability:

• Administered predominantly orally (via solution, blotter paper, gelatin, or sugar cubes). It is completely absorbed in the digestive tract with an estimated oral bioavailability of 71%. A preceding meal can delay absorption. 

Time Course: onest

30–45 minutes orally

• Time Course: peak tmax

Reached at approximately 1.0 to 2.5 hours post-oral ingestion.

• Time Course: Duration

• Acute effects persist for 9 to 12 hours. 

Metabolism

• Undergoes liver metabolism into inactive compounds primarily by cytochrome P450 enzymes; less than 1% is excreted unchanged. 

Elimination

• Elimination half-life (t1/2) is approximately 2.3 to 4.8 hours. Excreted primarily in urine within 8 hours, remaining detectable on toxicology screenings for up to 96 hours. 

Primary Mechanism:

• Acts as a partial agonist at serotonin 5-HT2A receptors. administration of the 5-HT2A antagonist ketanserin eliminates its acute subjective and psychedelic effects, confirming 5-HT2A activation as the primary mediator. 

Thalamocortical Gating:

• LSD binds to 5-HT2A receptors on thalamic neurons, impairing the thalamus’s capacity to filter external and internal sensory information directed to the cerebral cortex. This breakdown of sensory gating floods the cortex, resulting in perceptual anomalies, synesthesia, and cognitive disorganization. 

Physiological Safety & Toxicity:

• Has an extraordinarily wide therapeutic index. The animal LD50 is 16.5 mg/kg (rats) and 50–60 mg/kg (mice). In humans, an effective therapeutic dose is approximately 0.0003 to 0.001 mg/kg; the estimated lethal dose is roughly 50,000 to 100,000 times greater than the active dose. 

Subjective Phenomena:

• Alterations in visual and auditory perception (pseudohallucinations, illusions, closed-eye visuals), synesthesia (cross-modal sensory transfer, e.g., hearing colors), altered temporal processing, deep introspective euphoria, mystical-type experiences, and profound ego dissolution (loss of boundary between self and external environment). 

Somatic / Sympathetic Effects:

• Moderate sympathomimetic stimulation: pupil dilation (mydriasis), mild-to-moderate elevation in heart rate (tachycardia) and blood pressure, elevated body temperature (hyperthermia), diaphoresis (sweating), facial flushing, mild nausea, and transient appetite suppression. 

Contemporary Clinical Indications Generalized Anxiety Disorder (GAD):

• In a Phase 2 trial of MM-120 (lysergic acid d-tartrate), a single 100-μg clinical dose yielded a 7.7-point reduction on the Hamilton Anxiety Rating Scale (HAM-A) compared to placebo at 12 weeks, with a 65% clinical response rate and 48% clinical remission rate. The FDA granted MM-120 Breakthrough Therapy Designation in March 2024. 

Contemporary Clinical Indications Palliative Care & End-of-Life Distress:

• Placebo-controlled studies demonstrated that LSD-assisted therapy induces rapid, durable reductions in anxiety, depression, and existential demoralization in terminally ill patients lasting up to 16 weeks. 

Contemporary Clinical Indications Substance Use Disorders:

• Historical clinical data from the 1950s/60s established marked efficacy for alcohol use disorder; contemporary Phase 2 confirmatory trials are active in Switzerland. 

Absolute / Relative Contraindications:

• Personal or immediate family history of schizophrenia, bipolar mania, or psychotic disorders (due to risk of triggering prolonged psychotic episodes); active cardiovascular disease (due to sympathomimetic strain); and intense anticipatory fear or lack of psychological preparation. 

• Antidepressant Interactions: SSRIs/SNRIs:

• Acute use potentiates psychedelics; chronic administration downregulates 5-HT2A receptors, significantly blunting or extinguishing LSD's therapeutic effects. Requires a 2-week washout (or 6-week washout for fluoxetine due to its long-lived active metabolite norfluoxetine). 

• Antidepressant Interactions: Serotonin Syndrome:

• Concurrent administration with serotonergic enhancers presents a mild-to-moderate risk of life-threatening serotonin toxicity. 

• Antidepressant Interactions: Lithium

• Co-administration carries an established risk of precipitating acute epileptic seizures and severe delirium. 

Lysergic Acid Diethylamide (LSD-25):

• A synthetic ergoline compound classified as a classic hallucinogen/psychedelic, synthesized by reacting lysergic acid with diethylamine. 

Ergoline Alkaloids:

• A family of naturally occurring chemical compounds produced by the parasitic rye fungus Claviceps purpurea (ergot) that serve as chemical precursors to lysergic acid. 

5-HT2A Receptor:

• A major subtype of the G-protein coupled serotonin receptor expressed heavily in cortical pyramidal neurons and the thalamus; serves as the primary site mediating classic psychedelic effects. 

Cross-Tolerance:

• A pharmacological phenomenon wherein tolerance to one specific substance conveys immediate clinical tolerance to other substances operating via identical target mechanisms (e.g., LSD, psilocybin, and mescaline). 

Thalamocortical Gating:

• The neurobiological sensory-filtering process carried out by the thalamus to limit redundant sensory inputs from overwhelming cognitive awareness in the cerebral cortex. 

Synesthesia

• A neurological phenomenon wherein stimulation of one sensory or cognitive pathway leads to involuntary experiences in a secondary pathway (e.g., perceiving distinct colors upon hearing tones). 

Ego Dissolution:

The temporary, acute disruption of the psychological boundary separating an individual's conscious self from their surrounding sensory environment.

Entheogen

• A descriptive classification for psychoactive substances utilized primarily within sacred, ceremonial, or transpersonal spiritual contexts to generate transcendent experiences. 

Therapeutic Index (LD50/ED50):

• The quantitative ratio comparing the drug dose that produces toxic lethality in 50% of an animal cohort to the dose required to produce target therapeutic efficacy; high ratios signify substantial physical safety. 

Ketanserin

• A selective serotonin 5-HT2A receptor antagonist used experimentally to pharmacologically block or terminate the acute cognitive and somatic effects of classic psychedelics. 

Serotonin Syndrome:

• A toxic, hypermetabolic neurological condition provoked by excessive intrasynaptic serotonin, characterized clinically by autonomic instability, hyperthermia, clonus, tremor, and mental agitation. 

1938

• Dr. Albert Hofmann first synthesizes LSD-25 at Sandoz Laboratories in Basel, Switzerland, while examining lysergic acid derivatives for circulatory and respiratory stimulants. 

April 19, 1943 ("Bicycle Day"):

• Hofmann conducts the first intentional self-experimentation by ingesting 0.25 mg (250 μg) of water-soluble LSD tartrate, experiencing profound visual alterations and physical distress during his famous bicycle ride home accompanied by his laboratory assistant. 

1947

• Dr. Werner A. Stoll at the University of Zurich publishes the first clinical research investigating LSD in human subjects, noting profound psychiatric utility. Sandoz begins commercial distribution under the trade name Delysid. 

1970

Passage of the U.S. Controlled Substances Act places LSD into Schedule I, effectively freezing domestic academic and medical research for three decades.

March 2024:

• The FDA grants Breakthrough Therapy Designation to MM-120 (lysergic acid d-tartrate) for the clinical treatment of Generalized Anxiety Disorder. 

Quantitative Values & Equations

Therapeutic Ratio= Lethal Dose LD50///// Effective Dose ED50 = 50 to 60 mg/kg0.0003 to 0.001 mg/kg

≈50,000:1 to 100,000:1

Clinical LSD-Assisted Psychotherapy Protocol [Phase 1: Pre-Session Screening & Preparation]

• Rigorous exclusion of personal/family histories of bipolar or psychotic disorders

• Gradual medication tapering (SSRIs, SNRIs, MAOIs, Lithium)

• 1 to 3 non-drug preparation sessions: building rapport, establishing intentions, and trust

                     ↓

Clinical LSD-Assisted Psychotherapy Protocol [Phase 2: Dosing Session (Acute Administration)]

├── Administration of 100–200 μg oral LSD in a quiet, supportive environment

 ├── Presence of 1 to 2 trained co-therapists for the entire 8–12 hour active duration

 └── Inward-focused guidance (eye masks, curated music, minimal cognitive interference)

Clinical LSD-Assisted Psychotherapy Protocol [Phase 3: Integration Therapy]

├── Follow-up clinical sessions starting 24–72 hours post-session

 ├── Translating subjective breakthroughs and insights into cognitive and behavioral change

 └── Long-term monitoring of clinical anxiety, mood, and relational functioning

The Analogy:

Imagine your conscious brain as an exclusive, high-security executive office suite. Under normal everyday functioning, the thalamus acts as an expert executive secretary sitting right outside the door. Hundreds of internal and external stimuli (background office hums, subtle air movements, fluctuating internal heart rates, distant conversations, peripheral visual objects) arrive every second. The secretary intercepts 99% of this noisy mail, shredding the irrelevant clutter and delivering only a small, organized packet of vital memos to the executive (the cerebral cortex). This enables the executive to build a single, predictable narrative of reality and maintain a solid sense of identity. 

When LSD enters the brain, it acts like a counterfeit master key that slips into the locks on the secretary’s desk (thalamic 5-HT2A receptors). The secretary’s sorting mechanism is immediately disabled. The office doors fly open, and weeks of unfiltered, raw data rush onto the executive’s desk all at once. Sounds cross-wire into colors because auditory and visual inputs are delivered in the same unsorted mail delivery (synesthesia). The executive’s tidy organizational filing system completely collapses—they can no longer distinguish where the desk ends and the flood of incoming memos begins, temporarily breaking down their self-contained identity (ego dissolution). 

Misconception 1: "LSD physically damages human chromosomes and alters DNA."

• Clarification: This myth originated from an isolated, flawed 1967 in vitro laboratory paper that exposed isolated cell cultures to supranormal chemical concentrations[cite: 2]. Thorough in vivo scientific reviews and controlled human follow-up trials conclusively disproved this hypothesis by 1971; LSD does not cause genetic mutations or chromosomal damage in therapeutic or recreational dosage ranges.

Misconception 2: "A fatal overdose from LSD toxicity is a significant physiological danger."

• Clarification: LSD possesses an extraordinarily wide therapeutic index. The theoretical lethal dose in humans is estimated to be 50,000 to 100,000 times higher than an effective therapeutic dose (an active dose is ∼100 μg, requiring grams to reach lethal toxicity)[cite: 2]. Documented historical fatalities related to LSD stem almost exclusively from behavioral accidents, impaired decision-making, or suicide during uncontrolled "bad trips," rather than pharmacological organ failure or acute physiological overdose[cite: 2].

Misconception 3: "LSD is physically addictive, leading to compulsive cravings and physical withdrawal."

• Clarification: LSD does not stimulate physical drug dependence and produces no physiological withdrawal syndrome upon discontinuation. Furthermore, because repeated daily use induces immediate and virtually complete 5-HT2A receptor downregulation (tachyphylaxis), taking the drug on consecutive days yields almost zero subjective effect unless several days of abstinence are allowed to elapse.

Misconception 4: "Microdosing LSD has definitively proven clinical efficacy for psychiatric disorders."

• Clarification: While sub-perceptual microdoses (e.g., 10–25 μg) have widespread popular and naturalistic following, double-blind placebo-controlled empirical research remains sparse and mixed. Naturalistic ADHD and cognitive studies to date have lacked rigid placebo arms and remain vulnerable to significant expectancy and confirmation biases. The only current FDA Breakthrough Designation applies to full, single therapeutic doses (100 μg) paired with clinical oversight.